296 |
The Watchman FLX: advanced technology and step by step |
Hidehiko Hara |
Jul. 21. 21 |
295 |
Coronary Reaccess and PCI After TAVR: Tips and Tricks |
Didier Tchetche |
Jul. 21. 21 |
294 |
Coronary Protection during TAVR : When and How? |
Lars Sondergaard |
Jul. 21. 21 |
293 |
Novel Implant Techniques: What is Different? |
Eberhard Grube |
Jul. 21. 21 |
292 |
Optimal Valve Choice in Various TAVR: A Complex Equation to Select One |
Alan C. Yeung |
Jul. 21. 21 |
291 |
Antiplatelets Only Not Sufficient: Still Room for NOAC |
Jean-Philippe Collet |
Apr. 12. 21 |
290 |
TAVAR for Bicuspid Valve |
Dong Joon Lee |
Apr. 12. 21 |
289 |
Optimal Deployment Projection of TAVAR |
Seung Yong Lee |
Apr. 12. 21 |
288 |
Focus on the Patient Outcomes that Truly Matter: Clinical Perspective Update |
Rebecca Hahn |
Apr. 12. 21 |
287 |
Delivering the Outcomes You Demand with SAPIEN 3 |
Jeehoon Kang |
Apr. 12. 21 |